GALAD and BALAD-2 are statistical models for estimating the likelihood of the presence of hepatocellular carcinoma (HCC) in individual patients with chronic liver disease and the survival of patients with HCC, respectively. Both models use objective measures, particularly the serum markers a-fetoprotein (AFP), AFP-L3, and des-g-carboxyprothrombin. We aimed to validate these models in an international cohort of patients with HCC and assess their clinical performance.
W e recently developed a serum-based tool (GALAD) for the detection of hepatocellular carcinoma (HCC) based on the objective measures of Gender, Age and the 3 serologic biomarkers of a-fetoprotein (AFP), AFP-L3, and des-g-carboxyprothrombin (DCP), 1 all of which are commercially available on a single standard platform. 2 The model has the potential to be used in the surveillance setting and may mitigate some of the limitations of ultrasound scanning (USS), including limited sensitivity in obese patients and in patients with advanced cirrhosis. The former is of particular importance because obesity-related HCC accounts for an increasing percentage of HCC. [3] [4] [5] [6] [7] However, the model has not been validated in other countries where the underlying etiology of HCC is different. Although it appeared to perform as well in patients with early disease (defined as tumor size < 5 cm) as it did in patients with advanced disease, we did not undertake detailed analysis of the impact of tumor size on the utility of the model. This is of importance in the screening setting because the earlier the disease is detected the better the chance of curative treatment.
The same 3 biomarkers were combined with liver function tests (serum bilirubin and albumin) by Toyoda et al 8 to form the BALAD model (Bilirubin, Albumin, AFP-L3, AFP and DCP) for prognostication in HCC. A more rigorous statistical approach generated a second model (BALAD-2) that applied the same variables in a continuous rather than a categoric manner, 9 but, again, the model has not been validated in the international setting or at different disease stages.
We describe the application of these 2 models to cohorts from Germany, Japan, and Hong Kong.
Patients and Methods
We used cohorts from Germany, Japan, and Hong Kong ( Table 1 ). Both HCC and chronic liver disease (CLD) cohorts were used for GALAD validation and HCC patients were used only for BALAD-2 validation. CLD refers to liver disease that has lasted over a period of 6 months. Table 1 also reports the percentage of cases with cirrhosis.
The German cohort came from 4 large centers based at the University Hospital Essen (collected between 2005 and 2008), Hannover Medical High School (collected between 2008 and 2014), Leipzig (Evangelisches Krankenhaus Duisburg-Nord, collected between 2010 and 2013), and Mainz University Medical Centre (collected between 2003 and 2012). Overall, they comprised 1278 patients (275 HCC and 1003 patients with CLD alone).
The Japanese patients comprised 4476 patients (1514 with HCC and 2962 with CLD alone) and these were recruited from Ogaki Municipal Hospital where they initially were diagnosed as having HCC between 1988 and 2013.
The Hong Kong cohort (247 HCC patients) was recruited from the Prince of Wales Hospital, Department of Clinical Oncology, Chinese University of Hong Kong between 2009 and 2013. 10 For reference, the original UK cohort (on which the GALAD model initially was built and BALAD-2 was validated) was included in the analysis. These patients were recruited at the Queen Elizabeth Hospital (Birmingham, UK) and the NHS Foundation Trust (Newcastle Upon Tyne) between 2007 and 2012. The Birmingham cohort comprised 670 patients (331 with HCC and 339 with CLD alone), and the Newcastle cohort comprised 163 patients (63 with HCC and 100 with CLD alone).
We also included 229 patients with other hepatobiliary tract cancers (cholangiocarcinoma and pancreatic adenocarcinoma) ( Table 2) , and 92 healthy controls (Table 1) recruited also from the Queen Elizabeth Hospital (Birmingham, UK) between 2006 and 2012 and 2009 and 2011 respectively, to test the ability of the GALAD model to discriminate HCC from other hepatobiliary cancers and healthy controls. The hepatobiliary cohort was divided further into 3 subgroups: intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma.
None of the CLD control group had evidence of HCC at the time the relevant serum sample was taken or within a minimum follow-up period of 9 months (Table 1) . They were considered typical of those who would be included in a surveillance program. In all cohorts, the HCC patients had the 3 biomarkers measured within AE1.7 months of HCC diagnosis and before any treatment was administered.
The diagnosis of HCC was made according to international guidelines. 3, 4 Patients in the control groups had established chronic liver disease (on the basis of liver biopsy and/or typical clinical and imaging features). All patients had the 3 constituent biomarkers measured using the mTASWako i30 autoanalyzer (Wako Pure Chemical Industries, Ltd, Osaka, Japan). Patients with HCC were classified as having early (those receiving potentially curative therapy), intermediate (intra-arterial therapies), or advanced disease (systemic chemotherapy or supportive care).
In Japan, the biomarkers were, in both the HCC and control groups, undertaken as part of a surveillance program. In the other centers, they were collected specifically for this research study. The inclusion criterion was chronic liver disease (as defined earlier) with the presence or absence of cirrhosis specified.
In total, 7155 patients (2430 with HCC and 4725 with CLD) were involved in this study.
Assays of a-Fetoprotein, a-Fetoprotein-L3, and Des-g-Carboxyprothrombin AFP, AFP-L3, and DCP all were measured in the same serum sample. The measurements of high-sensitivity AFP-L3 (hs-AFP-L3) and DCP were achieved by using a microchip capillary electrophoresis and liquid-phase binding assay on a mTASWako i30 autoanalyzer. 2 The analytical sensitivity of the autoanalyzer is 0.3 ng/mL AFP, and the percentage of AFP-L3 can be measured when AFP is more than 0.3 ng/mL. 2 
Statistical Methods
Stata IC 12 software was used to perform the analyses.
GALAD. The GALAD model, as described previously, 1 uses the following equation: Z ¼ À10:08 þ 0:09 Â age þ 1:67 Â sex þ 2:34 log 10 ðAFPÞ þ 0:04 Â AFP-L3 þ 1:33 Â log 10 ðDCPÞ;
where sex ¼ 1 for males and 0 for females.
Taking the exponential (exp) of the linear predictor (Z), the probability of HCC (Pr(HCC)) in an individual patient (ranging from 0 to 1) can be estimated using the following equation:
To estimate sensitivity and specificity, 3 different sets of cut-off points were used in this study, as follows. First, the 3 original cut-off points as specified in the original GALAD study 1 (that were based on the overall UK cohort). Second, using the original UK cohort, 3 new cutoff points were generated using a subset of patients who had early stage HCC (within Milan Criteria). As in the original study, 1 cut-off point maximizes sensitivity while keeping specificity at 80%, the second maximizes specificity while keeping sensitivity at 80%, and the third maximizes the sum of sensitivity and specificity. Third, the same 3 optimized cut-off points, specific for Japan and Germany, also were reported. For Japan, this was generated from a subgroup within Milan Criteria, whereas in Germany this was based on the overall cohort because the number of early stage disease patients was too small for meaningful analysis.
The effect of tumor size (maximum tumor diameter) and etiology on the performance of the GALAD model was tested. Tumor size was recorded on the basis of an imaging procedure (computed tomography or magnetic resonance imaging scan). Unifocal tumor size ranges applied were as follows: smaller than 2, smaller than 3, smaller than 4, smaller than 5, and smaller than 10 cm, as well as those within the Milan criteria.
For the purpose of analysis, etiology was classified as hepatitis C virus (HCV)-or hepatitis B virus (HBV)related, or as other (mainly alcoholic liver disease). Although detailed data on alcohol consumption were available in the Japanese cohort, a distinct diagnosis of alcoholic cirrhosis was collected only in the UK and German cohorts. These were combined under "Europe" to test the performance of the model in an alcoholic cirrhosis cohort for comparison with the other etiologies.
The model performance also was tested in HCV patients depending on whether or not they had achieved sustained viral response status or, in case of HBV, if they were on active antiviral treatment. Detailed information was available only in the Japanese cohort. The number of cases receiving antiviral therapy in the German cohort was too small for a meaningful analysis.
By using the GALAD model, the area under the receiver operating characteristic (ROC) curves (AUROC), sensitivities, and specificities were generated for each cohort as a whole, and then as subgroups according to the tumor size and etiology classifications as described earlier. The 95% confidence intervals (CIs) for the AUROCs were constructed assuming a normal distribution for the area under the curve (asymptotic normal CIs). The performance of the GALAD model also was compared with that of the individual biomarkers. The equality of the ROC curves was tested using the method as described by DeLong et al. 11 BALAD-2. Survival was measured from the date of HCC diagnosis until the date of death or the date of the last follow-up evaluation. Patients undergoing transplantation (4.8% and 3.6% of the UK and German cohorts, respectively) ( Table 1) were not excluded from the analysis.
The BALAD-2 model 9 (built on a Japanese cohort and validated on a UK cohort), uses the following equation: where AFP was capped at 50,000 units. Both AFP and DCP are modeled as per 1000 units. AFP and DCP were in ng/ml. Bilirubin in mmol/L and albumin in g/LS.
To generate the 4 prognostic groups, cut-off points applied to the linear predictor such that if it is greater than 0.24 (risk 4, high), 0.24 to greater than -0.91 (risk 3), -0.91 to greater than -1.74 (risk 2), and -1.74 or less (risk 1, low). 
This equation was applied to all the HCC cohorts and separation of the prognostic groups assessed by Kaplan-Meier survival curves. The utility of the model also was tested by applying to subgroups according to treatment delivered.
The prognosis of HCC is widely assumed to be determined by underlying liver dysfunction and tumor-related factors. We hypothesized that BALAD-2 accurately reflected prognosis because it combined both of these, the former through bilirubin and albumin (BA) and the latter through the 3 biomarkers, AFP-L3, AFP and DCP (LAD). To test this hypothesis we first assessed the prognostic impact of underlying liver dysfunction, by applying the ALBI (Albumin-Bilirubin) grade, a recently proposed and validated instrument for assessing liver function in HCC. 12 We then used the European cohort (merged UK and Germany) the test the extent to which adding the tumor markers, that is, the BALAD model would increase the discriminatory utility of the ALBI grade using the Harrell-C statistic, 13, 14 and Akaike information criterion (AIC). 15 Harrell-C assesses the discriminative ability of the model by measuring the proportion of patient pairs for which the model correctly assigns lower risk to the patient who truly survives longest (ie, is at least risk). A good discriminative performance corresponds to a higher C-statistic. AIC measures the relative fit between models for a given set of data. A 4-point reduction (per additional covariate) is indicative of an improved model.
Cases with missing data (within bilirubin, albumin, AFP, AFP-L3, DCP, age, and sex) were excluded from the analysis; however, these made up only 1.7% and 1% of the GALAD and BALAD-2 data, respectively.
Results

GALAD
Demographic and clinical details of the cohorts are shown in Table 1 .
The model provided an overall AUROC of 0.93 (95% CI, 0.92-0.94) and 0.94 (95% CI, 0.93-0.96) for the Japanese and German validation cohorts, respectively (Supplementary Figure 1A) , only marginally lower than the figure for the original UK cohort (0.97, 95% CI, 0.96-0.98). GALAD also correctly classified HCC from other hepatobiliary cancers and healthy controls within the UK cohort showing AUROCs of 0.95 (95% CI, 0.93-0.96) and 0.97 (95% CI, 0.96-0.99), respectively (Supplementary Figure 1B and C) . The ROC curve results of the hepatobiliary cancer subgroups (pancreatic adenocarcinoma, extrahepatic cholangiocarcinoma, and intrahepatic cholangiocarcinoma) are shown in Supplementary Figure 2 . The AUROC derived from the model was superior (P < .0001) to that obtained if the biomarkers were used individually ( Figure 1A-C) . This was true both in the cohort overall and within the subset of early stage HCC patients (within Milan criteria) ( Figure 1D and E). Table 2 shows the figures for sensitivity, specificity, and the AUROC for all patients as well as those within the Milan criteria. Cut-off values for the GALAD model in Table 2 maximize the sum of sensitivities and specificities for each cohort.
The utility of the model was slightly lower in the smaller unifocal tumors, but remained in range of 0.85 to 0.95 (Figure 2A-C) . The AUROCs of patients with less than 2-cm unifocal tumors were 0.92 (95% CI, 0.85-0.997), 0.89 (95% CI, 0.88-0.91), and 0.93 (95% CI, 0.89-0.97) for the United Kingdom, Japan, and Germany, however, in the latter group the numbers were very small. Unifocal tumors less than 3 cm in the German series generated an AUROC of 0.87 (95% CI, 0.81-0.94). In those patients who were within Milan criteria, the corresponding AUROC figures were 0.93 (95% CI, 0.90-0.96) and 0.91 (95% CI, 0.90-0.92) in the United Kingdom and Japan cohorts, respectively ( Figure 2D and E).
There was no evidence of a difference (P > .05) in model performance between HBV, HCV, and other subgroups in the European cohorts. Although there was some evidence of difference between the etiologies in the Japanese cohort (P ¼ .0012), this was unlikely to be of clinical significance because the figures ranged only between 0.92 and 0.95 ( Supplementary Figure 3A-C) . Because of lower numbers of HCV and HBV subgroups within the UK and German cohorts, these were combined under "Europe" and the alcoholic etiology subgroup was added before generating GALAD AUROC curves (Supplementary Figure 3D ). This showed that the GALAD model performed equally well (P ¼ .7490) in all 4 etiologic subgroups.
In the Japanese series, performance of the GALAD model was not affected (P > .1) by the status of sustained viral response or active viral treatment in HCV and HBV patients, respectively ( Supplementary  Figure 4) .
The AUROC values as well as the sensitivity, specificity, and correctly classified percentages at the different cut-off values (whole cohort and subgroups) are summarized in Table 3 (UK-based cut-off values) and Supplementary Table 1 (country-specific cut-off values). The same data for the different etiologies in the combined European cohort (UK and Germany) are shown in Supplementary Table 2 .
BALAD-2
Applying the BALAD-2 model to the German and Hong Kong cohorts produced 4 clearly distinct and wellseparated HCC prognostic groups, hence confirming the utility of the model in the international setting ( Figure 3A -D, and the median survival at each BALAD-2 score in Figure 3E ). This separation remained when the analysis was confined to patients with a minimum of 18 months of follow-up evaluation (Supplementary Figure 5 ). BALAD-2 then was compared with the ALBI grade (Supplementary Figure 6) . The AIC and Harrell-C statistics clearly show that the BALAD-2 model was a better fit to the data than the ALBI model, as shown by the lower AIC and higher Harrell-C scores (5233.982 and 0.7012 for the BALAD-2, and 5469.059 and 0.6192 for the ALBI grade, respectively).
The BALAD-2 model proved equally discriminatory in all treatment classes ( Supplementary Figure 7) . UK and German cohorts were merged (as Europe) because the sample size for each treatment subgroup was relatively small.
Discussion
Our analysis validates the GALAD model by showing that it has utility outside the country in which it was developed (the United Kingdom). Both the German and Japanese data sets were particularly valuable in the validation setting. Each of the study cohorts was multicenter, the relevant biomarkers were measured in an external laboratory by an operator who had no knowledge of the clinical diagnosis, and the statistical analysis was undertaken at a third center where no further manipulation of the data was undertaken. In each of the 4 German centers, the AUROC was virtually identical and very close to that reported in the UK series. This was not surprising because the etiology and clinical features of HCC were very similar between Germany and the United Kingdom.
In Japan, these biomarkers currently are used individually or, more often, in concert to enhance routine ultrasound screening, 16 ,17 based on clinical experience rather than a formal statistical model. Combination of the markers increasingly is recognized to add utility to the individual biomarkers 18 and here we show that a formal, prospectively developed, statistical model that combines the markers is superior to individual markers alone. Furthermore, when the model performance was compared directly with results as obtained by the conventional combined use of the 3 markers in clinical practice in Japan, there was a clear improvement. Presumably this reflects the gain in information derived from the individual markers by treating them as continuous variables. Several recent studies have confirmed significant information loss when cut-off points were applied to continuous variables. 19, 20 The current analysis validates our original report in which small tumors were considered to be those with a maximum tumor size of 5 cm, but significantly extends the utility of the model by showing that, when unifocal tumors are considered, model performance remains remarkably good (AUROC > 0.85 for Germany and > 0.89 for other cohorts) and consistent down to less than 2 cm. This is perhaps not surprising because Marrero et al 21 reported that the overall performance of the individual biomarkers only decreased marginally in "early tumors." The utility of the GALAD model in early stage disease also has been reported in patients with early stage disease as assessed according to the Barcelona clinic liver cancer (BCLC) staging system 22 with similar results (BCLC 0, 0.97; BCLC A, 0.98; and BCLC B, 0.97) (Caviglia and Smedile, personal communication 2015).
The limitations of USS are acknowledged in the American Association for the Study of Liver Diseases guidelines in that performance characteristics have not been well defined in nodular cirrhotic livers and that "some patients, particularly the obese, are not good candidates [for surveillance] despite their risk." 4 The serologic approach has the specific advantage that it is not impacted by physical factors such as obesity, an increasingly recognized etiologic factor for HCC. 6, 7, 23 Our data suggest that the GALAD model is likely to detect tumors within the range that potentially curative therapies will be applicable. A further limitation of USS is that other primary liver tumors may be detected. In a recent analysis of surveillance in Japan (1994-2005), 4.4% of detected hepatic tumors ultimately were classified as cholangiocarcinoma. 24 Our data suggest that the GALAD model can discriminate successfully between HCC and cholangiocarcinoma ( Supplementary Figures 1B and 2) .
Having validated the GALAD model, it now requires testing in a prospective manner and we are aware that the 3 tumor markers involved in GALAD currently are being assessed prospectively in clinical trials in North America. From these it will be possible to assess the potential role of the GALAD model in the clinical surveillance setting.
Our analysis supports the clinically plausible view that the prognostic power of the BALAD-2 model is based on its ability to reflect both the degree of underlying liver dysfunction (bilirubin and albumin) and tumor-related factors (LAD). The general applicability of the model is underlined by the observation that discrimination is equally good, irrespective to the treatment applied.
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